Technical Analysis for NEXI - NexImmune, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 5.60 | -3.28% | -0.19 |
NEXI closed down 3.28 percent on Monday, March 18, 2024, on 5 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 26
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 200 DMA | Bearish | -3.28% | |
Narrow Range Bar | Range Contraction | -3.28% | |
Wide Bands | Range Expansion | -3.28% | |
Oversold Stochastic | Weakness | -3.28% | |
200 DMA Support | Bullish | -7.44% | |
Narrow Range Bar | Range Contraction | -7.44% |
Alert | Time |
---|---|
Down 5% | about 10 hours ago |
10 DMA Resistance | about 13 hours ago |
60 Minute Opening Range Breakdown | about 14 hours ago |
Down 3% | about 14 hours ago |
Up 5% | about 14 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/26/2024
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 28.6949 |
52 Week Low | 1.2501 |
Average Volume | 1,491,075 |
200-Day Moving Average | 5.96 |
50-Day Moving Average | 8.20 |
20-Day Moving Average | 6.54 |
10-Day Moving Average | 6.07 |
Average True Range | 1.13 |
RSI (14) | 37.89 |
ADX | 40.81 |
+DI | 34.18 |
-DI | 17.21 |
Chandelier Exit (Long, 3 ATRs) | 6.41 |
Chandelier Exit (Short, 3 ATRs) | 8.89 |
Upper Bollinger Bands | 7.98 |
Lower Bollinger Band | 5.10 |
Percent B (%b) | 0.17 |
BandWidth | 43.94 |
MACD Line | -0.63 |
MACD Signal Line | -0.58 |
MACD Histogram | -0.0523 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.47 | ||||
Resistance 3 (R3) | 6.53 | 6.31 | 6.33 | ||
Resistance 2 (R2) | 6.31 | 6.09 | 6.28 | 6.28 | |
Resistance 1 (R1) | 5.95 | 5.95 | 5.84 | 5.89 | 6.23 |
Pivot Point | 5.73 | 5.73 | 5.67 | 5.70 | 5.73 |
Support 1 (S1) | 5.37 | 5.51 | 5.26 | 5.31 | 4.97 |
Support 2 (S2) | 5.15 | 5.37 | 5.12 | 4.92 | |
Support 3 (S3) | 4.79 | 5.15 | 4.88 | ||
Support 4 (S4) | 4.73 |